Objective: The objective of this study was to assess the association between colorectal neoplasia and sporadic duodenal adenoma.
Background: Immunoproliferative small intestinal disease (also known as alpha chain disease) is a form of lymphoma that arises in small intestinal mucosa-associated lymphoid tissue (MALT) and is associated with the expression of a monotypic truncated immunoglobulin alpha heavy chain without an associated light chain. Early-stage disease responds to antibiotics, suggesting a bacterial origin. We attempted to identify a causative agent.
Methods: We performed polymerase chain reaction (PCR), DNA sequencing, fluorescence in situ hybridization, and immunohistochemical studies on intestinalbiopsy specimens from a series of patients with immunoproliferative small intestinal disease.
Results: Analysis of frozen intestinal tissue obtained from an index patient with immunoproliferative small intestinal disease who had a dramatic response to antibiotics revealed the presence of Campylobacter jejuni. A follow-up retrospective analysis of archival intestinalbiopsy specimens disclosed campylobacter species in four of six additional patients with immunoproliferative small intestinal disease.
Conclusions:
These results indicate that campylobacter and immunoproliferative small intestinal disease are associated and that C. jejuni should be added to the growing list of human pathogens responsible for immunoproliferative states. Effect of an oats-containing gluten-free diet on symptoms and quality of life in coeliac disease. A randomized study gluten-free diet were randomized to take either 50 g of oats-containing gluten-free products daily or to continue without oats for 1 year. Quality of life was assessed using the Psychological General Well-Being questionnaire and gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale. Small-bowel mucosal villous architecture, CD3+, AEâ+, ªä+ intraepithelial lymphocytes, serum endomysial and tissue transglutaminase antibodies were investigated.
Results: Twenty-three subjects were randomized to the oats-containing diet and 16 to the traditional glutenfree diet. All adhered strictly to their respective diet. Quality of life did not differ between the groups. In general, there were more gastrointestinal symptoms in the oats-consuming group. Patients taking oats suffered significantly more often from diarrhoea, but there was a simultaneous trend towards a more severe average constipation symptom score. The villous structure did not differ between the groups, but the density of intraepithelial lymphocytes was slightly but significantly higher in the oats group. The severity of symptoms was not dependent on the degree of inflammation. Antibody levels did not increase during the study period.
Conclusion:
The oats-containing gluten-free diet caused more intestinal symptoms than the traditional diet. Mucosal integrity was not disturbed, but more inflammation was evident in the oats group. Oats provide an alternative in the gluten-free diet, but coeliac patients should be aware of the possible increase in intestinal symptoms. 2004; 39:27-31. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial
Scand J Gastroenterol
Background: The role of Helicobacter pylori eradication in the management of gastro-oesophageal reflux disease (GORD) is controversial. We hypothesised that H. pylori eradication leads to worsened control of reflux disease.
Methods: Consecutive patients with weekly reflux symptoms were prospectively recruited for endoscopy and symptom evaluation. Patients were enrolled if they had H. pylori infection and required long term acid suppressants. Eligible patients were randomly assigned to omeprazole triple therapy (HpE group) or omeprazole with placebo antibiotics (Hp+ group) for one week. Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief. This was followed by a maintenance dose of 10 mg daily for up to 12 months. The primary study end point was the probability of treatment failure within 12 months, which was defined as either incomplete resolution of symptoms or oesophagitis at the initial treatment phase, or relapse of symptoms and oesophagitis during the maintenance phase. Predictors of treatment failure were determined by Cox's proportional hazards model.
Results: A total of 236 GORD patients were screened and 113 (47.9%) were positive for H. pylori; 104 (92%) patients were included in the intention to treat analysis (53 in the HpE group and 51 in the Hp+ group). Thirty one patients (30%) had erosive oesophagitis at baseline. H. pylori was eradicated in 98% of the HpE group and in 3.9% of the Hp+ group. Overall, 15 patients (28.3%) in the HpE group and eight patients (15.7%) in the Hp+ group had treatment failure. The 12 month probability of treatment failure was 43.2% (95% confidence interval (CI) 29.9-56.5%) in the HpE group and 21.1% (95% CI 9.9-32.3%) in the Hp+ group (log rank test, P ¼ 0.043). In the Cox proportional hazards model, after adjustment for the covariates age, sex, erosive oesophagitis, hiatus hernia, degree of gastritis, and severity of symptoms at baseline, H symptoms at baseline, H. pylori eradication was the only predictor of treatment failure (adjusted hazard ratio 2.47 (95% CI 1.05-5.85)). Background and aims: Prolonged lamivudine therapy is associated with treatment-resistant YMDD mutant hepatitis B virus (HBV). We evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hepatitis B (CHB) and YMDD mutant HBV.
Conclusion
Methods: Ninety-five patients with compensated CHB (group A) were randomized to adefovir 10 mg daily (n ¼ 46) or placebo (n ¼ 49) for 52 weeks while continuing treatment with lamivudine. Forty patients with decompensated hepatitis B or post-liver transplantation (group B) received adefovir and lamivudine. The primary end point was a decline in serum HBV DNA level to 10(5) copies/ml or a .2 log(10) reduction from baseline at weeks 48 and 52.
Results: HBV DNA response occurred in 85% of patients (39 of 46) in group A given combined therapy versus 11% (5 of 46) receiving lamivudine alone (P , 0.001), with a significant change in HBV DNA level from baseline (P , 0.001) between treatment groups (median, À4.6 vs. +0.3 log(10) copies/ml, respectively). Normalization of alanine aminotransferase levels occurred in 31% of patients (14 of 45) receiving combined therapy versus 6% (3 of 48) receiving lamivudine alone (P ¼ 0.002). Ninety-two percent of patients (36 of 39) in group B had an HBV DNA response (median change of À4.6 log(10) copies/ml) and improved liver chemistries (P , or ¼ 0.001). Both treatment regimens were well tolerated, and renal function abnormalities were not observed in either group.
Conclusions: The addition of adefovir dipivoxil to lamivudine in patients with CHB with compensated or decompensated liver disease due to YMDD mutant HBV is associated with virologic and biochemical improvement during 52 weeks of treatment and is well tolerated. Background and aims: To search for changes in body composition and energy metabolism associated with the repeatedly observed weight gain of cirrhotic patients after portosystemic shunting.
Methods: Twenty-one patients were studied prospectively before and 6 and 12 months after transjugular intrahepatic portosystemic shunt (TIPS) to assess body cell mass by two independent methods (total body potassium counting: body cell mass determined by TBP, BCM(TBP), bioelectric impedance analysis: body cell mass determined by BIA, BCM(BIA)), muscle mass (anthropometry), resting energy expenditure (REE(CA-LO)) by indirect calorimetry, and nutritional intake by dietary recall analysis.
Results: Prior to TIPS patients were hypermetabolic in terms of measured vs. predicted REE (REE(CALO) median 1423 (range 1164-1838) vs. REE(PRED) 1279 (1067-1687) kcal; P , 0.05) and their body cell mass was lower (19.1 (10.9-33.4) vs. 31.7 (16.8-47 .1) kg; P ¼ 0.001). After TIPS body cell mass (BCM(BIA)) increased to 23.5 (12.7-44. 3) (P , 0.025) and 25.7 (14.2-39.7) kg (P ¼ 0.05) at 6 and 12 months after TIPS and this was confirmed by total potassium counting (BCM(TBP) before TIPS: 18.8 (10.6-26.7) vs. 22.4 (12.9-28.5) kg at 6 months; P , 0.01). Hypermetabolism persisted throughout the study period. Energy and protein intake increased significantly by 26 and 33%.
Conclusions: An increase of prognostically relevant variables body cell and muscle mass contributes to the weight gain after TIPS in malnourished patients with cirrhosis and hypermetabolism. 
